BioAtla outlines $800M peak sales target for Oz-V as FDA alignment paves way for phase III launch (NASDAQ:BCAB)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...